331 related articles for article (PubMed ID: 1689677)
41. Pre-analytical and biological variability of prostatic acid phosphatase and prostate-specific antigen in serum from patients with prostatic pathology.
Panteghini M; Pagani F; Bonora R
Eur J Clin Chem Clin Biochem; 1992 Mar; 30(3):135-9. PubMed ID: 1376155
[TBL] [Abstract][Full Text] [Related]
42. Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners.
Van der Meer S; Kollen BJ; Hirdes WH; Steffens MG; Hoekstra-Weebers JE; Nijman RM; Blanker MH
BJU Int; 2013 Jul; 112(1):26-31. PubMed ID: 23465178
[TBL] [Abstract][Full Text] [Related]
43. [Metastasis and markers].
Trinchieri A; Rovera F; Longo G; Del Nero A; Zanetti G; Austoni E
Arch Ital Urol Nefrol Androl; 1992 Mar; 64(1):27-30. PubMed ID: 1373913
[TBL] [Abstract][Full Text] [Related]
44. Immunohistochemical labelling for prostate specific antigen in non-prostatic tissues.
Alanen KA; Kuopio T; Koskinen PJ; Nevalainen TJ
Pathol Res Pract; 1996 Mar; 192(3):233-7. PubMed ID: 8739470
[TBL] [Abstract][Full Text] [Related]
45. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.
Oesterling JE
J Urol; 1991 May; 145(5):907-23. PubMed ID: 1707989
[TBL] [Abstract][Full Text] [Related]
46. Nucleolar organizer regions in prostatic adenocarcinomas. Comparison with flow cytometric analysis, tumor grade, stage and serum prostate-specific antigen levels.
Alivizatos G; Pavlaki K; Giannopoulos A; Mitropoulos D; Tsega A; Deliveliotis C; Dimopoulos C
Eur Urol; 1992; 21(2):141-5. PubMed ID: 1379922
[TBL] [Abstract][Full Text] [Related]
47. Contemporary role of prostate cancer gene 3 in the management of prostate cancer.
Roobol MJ
Curr Opin Urol; 2011 May; 21(3):225-9. PubMed ID: 21301341
[TBL] [Abstract][Full Text] [Related]
48. Hormonal modulation of biosynthesis of prostatic specific antigen, prostate specific acid phosphatase and prostatic inhibin peptide.
Sheth AR; Garde SV; Mehta MK; Shah MG
Indian J Exp Biol; 1992 Mar; 30(3):157-61. PubMed ID: 1380948
[TBL] [Abstract][Full Text] [Related]
49. [PSA variations in persons with latent prostate cancer].
Stamatiou K; Danciu M; Karakos C; Sofras F
Rev Med Chir Soc Med Nat Iasi; 2008; 112(1):126-9. PubMed ID: 18677916
[TBL] [Abstract][Full Text] [Related]
50. Prostate-specific antigen in management of prostatic carcinoma.
Brawer MK; Lange PH
Urology; 1989 May; 33(5 Suppl):11-6. PubMed ID: 2469244
[TBL] [Abstract][Full Text] [Related]
51. Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia.
Pretlow TG; Pretlow TP; Yang B; Kaetzel CS; Delmoro CM; Kamis SM; Bodner DR; Kursh E; Resnick MI; Bradley EL
Int J Cancer; 1991 Nov; 49(5):645-9. PubMed ID: 1718912
[TBL] [Abstract][Full Text] [Related]
52. The laboratory diagnosis of prostatic adenocarcinoma.
Griffiths JC
Crit Rev Clin Lab Sci; 1983; 19(3):187-204. PubMed ID: 6144453
[TBL] [Abstract][Full Text] [Related]
53. The "hook effect": high concentrations of prostate-specific antigen giving artifactually low values on one-step immunoassay.
Wolf BA; Garrett NC; Nahm MH
N Engl J Med; 1989 Jun; 320(26):1755-6. PubMed ID: 2471931
[No Abstract] [Full Text] [Related]
54. Clinical applications of molecular biomarkers in prostate cancer detection.
Dumache R; Miclea F; Bumblăcilă B; Puiu M
Rev Med Chir Soc Med Nat Iasi; 2010; 114(2):470-5. PubMed ID: 20700989
[TBL] [Abstract][Full Text] [Related]
55. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.
Carter HB; Pearson JD; Metter EJ; Brant LJ; Chan DW; Andres R; Fozard JL; Walsh PC
JAMA; 1992 Apr 22-29; 267(16):2215-20. PubMed ID: 1372942
[TBL] [Abstract][Full Text] [Related]
56. Prostate-specific antigen (PSA) in the management of 500 prostatic patients.
Guillet J; Role C; Duc AT; François H
Am J Clin Oncol; 1988; 11 Suppl 2():S61-2. PubMed ID: 2468274
[TBL] [Abstract][Full Text] [Related]
57. Prostate specific antigen. A review.
Brawer MK
Acta Oncol; 1991; 30(2):161-8. PubMed ID: 1709355
[TBL] [Abstract][Full Text] [Related]
58. The diagnostic value of urinary transferrin compared to serum prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) in patients with prostatic cancer.
van Dieijen-Visser MP; Hendriks MW; Delaere KP; Gijzen AH; Brombacher PJ
Clin Chim Acta; 1988 Sep; 177(1):77-80. PubMed ID: 2460272
[TBL] [Abstract][Full Text] [Related]
59. New tests for prostate cancer may be nearing the clinic.
Tuma RS
J Natl Cancer Inst; 2010 Jun; 102(11):752-4. PubMed ID: 20498428
[No Abstract] [Full Text] [Related]
60. Papillary cystoadenocarcinoma of the prostate.
Takeuchi S; Higashi Y; Kobayashi I; Takahama M
Hinyokika Kiyo; 1992 Mar; 38(3):347-9. PubMed ID: 1381865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
